Thomas M. Renaud Sign in to save

ORCID 0000-0002-4895-6090 OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

–

Works (all)

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (9)

2× Janssen Research & Development, Raritan, NJ, USA
2× Janssen Research & Development, Raritan, USA
1× Janssen Research and Development, Raritan, NJ
1× Janssen Research & Development, Raritan, United States
1× 10Janssen Research & Development, Raritan, NJ
1× 19Janssen Research & Development, Raritan, NJ
1× Janssen Research & Development, Raritan, NJ
1× Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, Netherlands
1× 4Janssen Research & Development, Raritan, NJ

Papers 9 stored

All · Aachen affiliation only

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
2025 The Lancet Haematology article Medicine Multiple Myeloma Research and Treatments Open access

113

citations
Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
2024 Blood conference-abstract Medicine Multiple Myeloma Research and Treatments

1

citations
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab
2024 Clinical Lymphoma Myeloma & Leukemia article Medicine Multiple Myeloma Research and Treatments Open access

49

citations
Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study
2023 Blood conference-abstract Medicine Multiple Myeloma Research and Treatments

50

citations
Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study
2023 Blood conference-abstract Medicine Multiple Myeloma Research and Treatments

18

citations
POSTER: MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1
2023 Clinical Lymphoma Myeloma & Leukemia article Medicine Multiple Myeloma Research and Treatments

1

citations
MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1
2023 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Multiple Myeloma Research and Treatments Open access

1

citations
P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1
2023 HemaSphere article Medicine Multiple Myeloma Research and Treatments Open access

4

citations
Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.
2023 Journal of Clinical Oncology conference-abstract Medicine Multiple Myeloma Research and Treatments

17

citations

9 results

Thomas M. Renaud ▲ Sign in to save

Departments & institutes in Aachen

Papers 9 stored

Thomas M. Renaud Sign in to save